Zhe Wei

Prof. Dr. Zhe Wei


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
RYRuhui Yang
Ruhui Yang
ZHzhiyong hu
zhiyong hu
PZPengyong Zhang
Pengyong Zhang
SWSongquan Wu
Songquan Wu
ZSZhaoxia Song
Zhaoxia Song
ZWZhe Wei
Zhe Wei
Probucol has antioxidant effects and inhibits inflammation. Farnesoid X receptor (FXR) is a nuclear receptor that regulates autophagy, which is regarded as the key cause of the activation of hepatic stellate cell (HSC). In this study, the effects of probucol on HSC activation and autophagy in vitro and vivo and the role of FXR in this progress were investigated. Results showed that probucol ameliorated hepatic fibrosis and autophagy, and increased the expression of FXR in liver in a mouse model of fibrosis induced by CCl4. And probucol could alleviate lipopolysaccharide-induced autophagy and HSC activation in vitro. In addition, probucol increased FXR expression, and the Z-guggulsterone, an antagonist of FXR, could block the effects of probucol on HSC activation and autophagy. Additionally, agonists of FXR could suppress LPS-induced autophagy and activation. These results suggest that probucol could ameliorate hepatic fibrosis, and inhibit HSC autophagy and activation, and these effects are associated with FXR.

30 November 2023 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
JWJin-Jing Wu
Jin-Jing Wu
ZWZhe Wei
Zhe Wei
Alzheimer’s disease (AD) is a central nervous system (CNS) degenerative disorder, is caused by various factors including β-amyloid toxicity, hyperphosphorylation of tau protein, oxidative stress, and others. The dysfunction of microglia has been associated with the onset and advancement of different neurodevelopmental and neurodegenerative disorders, such as AD. The gut of mammals harbors a vast and complex population of microorganisms, commonly referred to as the microbiota. There’s a growing recognition that these gut microbes are intrinsically intertwined with mammalian physiology. Through the circulation of metabolites, they establish metabolic symbiosis, enhance immune function, and establish communication with different remote cells, including those in the brain. The gut microbiome plays a crucial part in influencing the development and performance of microglia, as indicated by recent preclinical studies. Dysbiosis of the intestinal flora leads to alterations in the microglia transcriptome that regulate the interconversion of microglia subtypes. This conversation explores recent research that clarifies how gut bacteria, their byproducts, and harmful elements affect the activation and characteristics of microglia. This understanding opens doors to innovative microbial-based therapeutic strategies for early identification and treatment goals in AD.

12 April 2020 in Journal of Periodontal Research
Verified
Journal Article
Closed access
PDF file
YKYi Kang
Yi Kang
RYRuhui Yang
Ruhui Yang
ZWZhe Wei
Zhe Wei
DZDaqun Zhu
Daqun Zhu
TTTingbing Tang
Tingbing Tang
GZGuangyu Zha
Guangyu Zha

11 June 2019 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
RYRuhui Yang
Ruhui Yang
ZWZhe Wei
Zhe Wei
SWSongquan Wu
Songquan Wu
Here, we used lumiflavin, an inhibitor of riboflavin, as a new potential therapeutic chemosensitizer to ovarian cancer stem‐like cells (CSCs). This study demonstrates that the enrichment of riboflavin in CSCs is an important cause of its resistance to chemotherapy. Lumiflavin can effectively reduce the riboflavin enrichment in CSCs and sensitize the effect of cisplatin Diamminedichloroplatinum (DDP) on CSCs. In this study, CSCs of human ovarian cancer cell lines HO8910 were separated using a magnetic bead (CD133+). We also show the overexpression of the mRNA and protein of riboflavin transporter 2 and the high content of riboflavin in CSCs compared to non‐CSCs (NON‐CSCs). Moreover, CSCs were less sensitive to DDP than NON‐CSCs, whereas, the synergistic effect of lumiflavin and DDP on CSCs was more sensitive than NON‐CSCs. Further research showed that lumiflavin had synergistic effects with DDP on CSCs in increasing mitochondrial function damage and apoptosis rates and decreasing clonic function. In addition, we found that the combination of DDP and lumiflavin therapy in vivo has a synergistic cytotoxic effect on an ovarian cancer nude mice model by enhancing the DNA‐damage response and increasing the apoptotic protein expression. Notably, the effect of lumiflavin is associated with reduced riboflavin concentration, and riboflavin could reverse the effect of DDP in vitro and in vivo. Accordingly, we conclude that lumiflavin interfered with the riboflavin metabolic pathways, resulting in a significant increase in tumour sensitivity to DDP therapy. Our study suggests that lumiflavin may be a novel treatment alternative for ovarian cancer and its recurrence.

29 November 2024 in Medicine
Verified
Journal Article
Open access
XYXinyue Yang
Xinyue Yang
HMHe Min
He Min
QTQingqing Tang
Qingqing Tang
CJCao Jiazhen
Cao Jiazhen
ZWZhe Wei
Zhe Wei
MSMengmeng Sun
Mengmeng Sun
To demonstrate the potential for connecting metabolomics with traditional Chinese medicine (TCM) external therapies such as acupuncture and moxibustion, we conducted a literature review on metabolomics as a measurement tool for determining the efficacy of various TCM external therapies. Human research and animal models published in the last 10 years were summarized. The investigation can be classified as follows: Using metabolomics to study metabolic profile changes produced by stimulation of a specific acupoint ST36 indicates the perturbation of metabolites produced by stimulation of acupoints by external TCM treatments can be characterized by metabolomics; and Using metabolomics to reveal the molecular mechanism of various TCM external therapy methods to treat specific diseases such as digestive system disease, cardiovascular disease, neurological disorder, bone disease, and muscle fatigue. We conclude that metabolomics has considerable potential for comprehending TCM external treatment interventions, particularly from a systems perspective. Linking TCM external therapy research with metabolomics can further bridge detailed biological mechanisms with the systematic effect of TCM external therapy, hence providing new paths for gaining a deeper knowledge of the importance of TCM in the treatment and maintenance of health.

27 September 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZWZhe Wei
Zhe Wei
JWJinjing Wu
Jinjing Wu
XWXinlin Wang
Xinlin Wang
JYJinghua Yi
Jinghua Yi
ZLZihe Liu
Zihe Liu
JGJing Gong
Jing Gong
Alzheimer’s disease (AD) is increasingly viewed as a disorder involving systemic immune and metabolic changes, but how gut microbial composition, fecal metabolites, and peripheral immune proteins vary across the AD clinical continuum remains unclear. We conducted a cross-sectional multi-omics study of 78 participants, including cognitively healthy controls (CH), individuals with mild cognitive impairment (MCI), and patients with AD. Fecal 16 S rRNA gene sequencing, fecal untargeted metabolomics, selected serum immune proteins, and AD-related blood biomarkers were analyzed using group comparisons and exploratory integrative analyses. Cognitive scores were consistent with the predefined CH, MCI, and AD classifications. Blood biomarker and peripheral immune protein analyses showed group-dependent patterns, including higher Aβ1–42 and p-tau-181 in cognitively impaired groups than in CH, the highest NfL and MCP-1 levels in AD, higher sTREM2 and PGRN in cognitively impaired groups, and lower CX3CL1 in MCI and AD. Microbiome beta-diversity analyses did not support robust categorical separation among groups, whereas selected genus-level analyses highlighted lower relative abundance of Faecalibacterium and Agathobacter and higher relative abundance of Faecalitalea in cognitively impaired groups. Fecal metabolomics highlighted alterations involving lipid/fatty acyl-, bile acid-, and amino acid/peptide-related metabolism, including 3-methyladipic acid, linoleoyl ethanolamide, lauroyl-l-carnitine, cholic acid, 7-ketodeoxycholic acid, and α-l-Glu-Gly. Integrative analyses suggested fecal metabolites as possible statistical links between gut microbial features and peripheral immune or cognitive readouts. These findings provide hypothesis-generating evidence for gut microbiota–fecal metabolite–peripheral immune associations across the AD continuum and require validation in larger longitudinal cohorts.